NCT07224191 Hippocampal Oscillations During Exploration
| NCT ID | NCT07224191 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2026-02-25 |
| Primary Completion | 2028-10-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2026-02-25 with a primary completion date of 2028-10-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to determine how visuomotor exploration relates to hippocampal activity along its long axis. The study will investigate the neurophysiological mechanisms in the hippocampus during (1) visual exploration in surgical patients using high-resolution iEEG, and (2) ambulatory exploration in patients implanted with RNS devices.
Eligibility Criteria
Inclusion Criteria: All subjects: * Adults (18-70 years) * Able to provide informed consent Aim 1: Surgical epilepsy patients' inclusion criteria * Implanted hippocampal depth electrodes for Stage 1 epilepsy surgery * IQ=\>80\* Aim 2: RNS patients Inclusion criteria * Implanted RNS device with at least one hippocampal depth electrode * At least 5 months post-implantation to avoid the post-implant effect * Have a relatively low number of seizures, defined as =\<1 debilitating seizure per week * Able to walk and wear research equipment without assistance * IQ\>=80 Aim 2: Healthy Control Inclusion criteria • Able to walk and wear research equipment without assistance Exclusion Criteria: RNS patients, Aim 2: • Any generalized tonic-clonic seizure(s) within the last year All subjects: * Legally blind * Smoking tobacco, marijuana, recreational drugs or alcohol use within 1 week of cognitive testing * Unable to give informed consent * Pregnancy
Contact & Investigator
Anli Liu, MD, MA
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT07224191 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07224191 currently recruiting?
Yes, NCT07224191 is actively recruiting participants. Contact the research team at Anli.Liu@nyulangone.org for enrollment information.
Where is the NCT07224191 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07224191 clinical trial?
NCT07224191 is sponsored by NYU Langone Health. The principal investigator is Anli Liu, MD, MA at NYU Langone Health. The trial plans to enroll 56 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.